Failure of stavudine-lamivudine combination therapy in antiretroviral-naive patients with AZT-like HIV-1 resistance mutations

Journal of Medical Virology

Volumn 65, Issue 4, 2001, Pages 631-636

  Sarmati, Loredana ^a,b   Nicastri, Emanuele ^a,c,d,e   Parisi, Saverio Giuseppe ^a,f,g   D'Ettorre, Gabriella ^a,h   Narciso, Pasquale ^a,b   Mancino, Giorgio ^a   Gallo, Isa ^a,b   Abbadessa, Vincenzo ^a   Dalle, Nogare Ernesto Renato ^a,b,c,d,e   Traina, Cino ^a   Vullo, Vincenzo ^a   Andreoni, Massimo ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^e Umberto I Hospital   (Italy)

^f UNIVERSITY OF PALERMO   (Italy)

^g Casa del Sole Hospital   (Italy)

^h ASL 6   (Italy)

Author keywords

Antiretroviral therapy; AZT resistance; Stavudine lamivudine combination therapy

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; LYMPHOCYTE COUNT; MONONUCLEAR CELL; NUCLEOTIDE SEQUENCE; PHENOTYPE; POLYMERASE CHAIN REACTION; TREATMENT FAILURE; VIRUS ISOLATION; VIRUS MUTATION;

ANTI-HIV AGENTS; COHORT STUDIES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; LAMIVUDINE; MUTATION; STAVUDINE; TREATMENT FAILURE; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0035214534     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.2083     Document Type: Article

References (21)

1. Virological basis for HIV-1 resistance to stavudine investigated by analysis of clinical samples
2. Antiretroviral therapy in adults updated recommendations of the International AIDS Society - USA Panel
3. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine
4. I178M in HIV-1RT is associated with in vitro d4T resistance and d4T failure in some therapy-naive pediatric patients
5. Changes in the capacity of lamivudine-resistant HIV-1 to infect susceptible cells
6. Substantial correlation between HIV-1 drug-associated resistance mutations in plasma and peripheral blood mononuclear cells in heavily treated patients
7. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine
8. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
9. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro
10. Decline in deaths from AIDS due to new antiretrovirals
11. Improved survival among HIV-infected individuals after initiation of antiretroviral therapy
12. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine
13. Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection
14. Two distinct mutational pathways in HIV-1 RT confer zidovudine/lamivudine dual resistance
15. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy
16. Stavudine resistance: An update on susceptibility following prolonged therapy
17. The ALBI trial: A randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus
18. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy
19. D4T based combination therapy selects for "AZT Like" HIV-1 resistance mutations in AZT naive adult patients
20. Mutations in retroviral genes associated with drug resistance: 1999-2000 Update
21. Impairment of stavudine (d4T) phosphorylation in patients receiving a combination of zidovudine and d4T (ACTG290)